30th Mar 2007 13:57
Ark Therapeutics Group PLC30 March 2007 TR-1: NOTIFICATION OF MAJOR INTERESTS IN SHARES (1). Identity of the issuer or the underlying issuer of existing shares to whichvoting rights are attached: ARK THERAPEUTICS GROUP PLC 2. Reason for the notification (please state Yes/No): N/A An acquisition or disposal of voting rights: ( ) An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached: ( ) An event changing the breakdown of voting rights: ( ) Other: Transitional disclosure required following the implementation ( x )of the DTR rules 3. Full name of person(s) subject to the notification obligation: Hansa Trust plc 4. Full name of shareholder(s) (if different from 3.): N/A 5. Date of the transaction and date on which the threshold is crossed or reachedif different): N/A 6. Date on which issuer notified: 30 March 2007 7. Threshold(s) that is/are crossed or reached: N/A 8. Notified details: A: Voting rights attached to shares Class/type of shares: Ordinary GB0034251727 Situation previous to the triggering transaction: Number of shares: Number of voting Rights: Resulting situation after the triggering transaction: Number of shares: Direct: Number of voting rights: Direct: 5,375,000 Indirect: % of voting rights: Direct: 3.24% Indirect: B: Financial Instruments N/A Resulting situation after the triggering transaction: Type of financial instrument: Expiration Date: Exercise/conversion period/date: Number of voting rights that may be acquired if theinstrument is exercised/converted. % of voting rights: Total (A+B) Number of voting rights: 5,375,000 % of voting rights: 3.24% 9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: Proxy Voting: 10. Name of the proxy holder: N/A 11. Number of voting rights proxy holder will cease to hold: N/A 12. Date on which proxy holder will cease to hold voting rights: N/A 13. Additional information: N/A 14. Contact name: N/A 15. Contact telephone number: N/A 16. Contact name and telephone at issuer NICK PLUMMER Company Secretary Ark Therapeutics Group plc 020 7388 7722 30 March 2007 This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
PVG.LHansa Inv.